Complement is a complex protein network of plasma, and an integral part of the innate
immune system. Complement activation results in the rapid clearance of bacteria by immune …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Eculizumab has opened new horizons in the treatment of complement-mediated disorders.
Prophylactic and immunization strategies against the risk of Nesseria spp. infections are …

Pulmonary hypertension (PH) is a progressive lethal disease, which is characterized by
abnormal vascular remodeling and persistently elevated pulmonary artery pressure …

Despite its considerable morbidity and mortality, paroxysmal nocturnal haemoglobinuria
(PNH) is still underdiagnosed. Patients with PNH can suffer from cardiovascular …

Paroxysmal nocturnal hemoglobinuria (PNH) is caused by acquired gene mutations
resulting in deficiency of glycosylphosphatidylinositol (GPI)–anchored complement …

Bone marrow failure (BMF) syndromes are a heterogenous group of non-malignant
hematologic diseases characterized by single-or multi-lineage cytopenia (s) with either …

Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐
week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal …

Paroxysmal nocturnal hemoglobinuria is a rare acquired hematologic disorder, the most
serious complication of which is thrombosis. The increased incidence of thrombosis in …

Paroxysmal Nocturnal Hemoglobinuria (PNH) constitutes a rare bone marrow failure
syndrome characterized by hemolytic anemia, thrombotic events (TEs), and bone marrow …